Dan Curran is a co-founder and Managing Partner of Mountainfield Venture Partners. Trained as a physician-scientist, he has more than 25 years of broad biopharmaceutical experience ranging from drug development to business development to venture investing.
Prior to Mountainfield, Dan was Senior Vice President and Head of Rare Disease Therapeutic Area for Takeda Pharmaceutical Company. During his tenure, his organization achieved global regulatory approvals for four new medicines, TAKHZYRO, VONVENDI, LIVTENCITY, and ADZYNMA, which have transformed the treatment of hereditary angioedema (HAE), von Willebrand’s disease, cytomegalovirus (CMV) infections, and thrombotic thrombocytopenic purpura (TTP).
Previously, Dan was Senior Vice President and Head of the Center for External Innovation (CEI) at Takeda responsible for all R&D business development, venture investments, and academic alliances. Over four years, his team concluded more than 150 transactions, enhancing the pipeline with collaborations across numerous therapeutic areas and modalities. In this capacity, Dan also directed Takeda’s venture investments and managed a portfolio of more than 40 companies and greater than $900M of invested capital generating a return of >3x. Under his leadership, Takeda also worked closely with the investment community to form numerous innovative spin-out companies, including Myovant (NASDAQ: MYOV), Phathom Pharmaceuticals (NASDAQ: PHAT), and Day One Pharmaceuticals (NASDAQ: DAWN).
Prior to his leadership of Takeda’s CEI, Dan led the corporate development group at Millenium Pharmaceuticals and was a member of the executive management team. Previous experiences include a business development role at DuPont Merck.
Dan received an MD from the University of Pennsylvania School of Medicine and an MBA from the University of Pennsylvania’ Wharton School. He graduated Summa cum laude from King’s College with a degree in Chemistry.